Procedure guidelines for radioiodine therapy of differentiated thyroid cancer (version 3);Verfahrensanweisung zur radioiodtherapie (RIT) beim differenzierten schilddrüsenkarzinom (version 3)

NuklearMedizin

Volumn 46, Issue 5, 2007, Pages 213-219

  Dietlein, M ^a,b   Dressler, J ^a,c   Eschner, W ^a,b   Grunwald F ^a,d   Lassmann, M ^a,e   Leisner, B ^a,f   Luster, M ^a,e   Moser, E ^a,g   Reiners, Chr ^a,e   Schicha, H ^a,b   Schober, O ^a,h  

^a Deutsche Gesellschaft für Nuklearmedizin ^*

^b UNIVERSITY OF COLOGNE   (Germany)

^c Henriettenstiftung   (Germany)

^d GOETHE UNIVERSITY   (Germany)

^e UNIVERSITY OF WÜRZBURG   (Germany)

^f DEPARTMENT OF CARDIOLOGY   (Germany)

^g UNIVERSITY OF FREIBURG   (Germany)

^h UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Differentiated thyroid cancer; Dosimetry; Guidelines; Radioiodine ablation; Radioiodine therapy; Recombinant human thyrotropin

Indexed keywords

IODINE 131; RECOMBINANT THYROTROPIN; THYROID HORMONE;

CONTRACEPTION; DENTAL CARIES; DOSIMETRY; DRUG WITHDRAWAL; FAMILY PLANNING; HUMAN; HYPOTHYROIDISM; MOUTH HYGIENE; REVIEW; SALIVARY GLAND; SENSITIVITY ANALYSIS; THYROID CANCER; WHOLE BODY SCINTISCANNING; XEROSTOMIA;

HUMANS; IODINE RADIOISOTOPES; NEOPLASM METASTASIS; PRACTICE GUIDELINES AS TOPIC; THYROID NEOPLASMS;

EID: 35348957944     PISSN: 00295566     EISSN: None     Source Type: Journal    
DOI: 10.1160/nukmed-0286     Document Type: Review

References (30)

1. Biermann M, Schober O. Should high hTg levels in the absence of iodine uptake be treated? Eur J Nucl Med Mol Imaging 2003; 30: 160-163.
2. nd Ed. Berlin: Springer 2005.
3. Cooper DS, Doherty GM, Haugen BR et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2006; 16: 1-33.
4. Deutsche Krebsgesellschaft. Interdisziplinäre Leitlinie der Deutschen Krebsgesellschaft und der Deutschen Gesellschaft für Chirurgie. Maligne Schilddrüsentumoren. 2006. www.uni-duesseldorf.de/AWMF.
5. Dietlein M, Dressler J, Eschner W et al. Procedure guideline for radioiodine test (version 3). Nuklearmedizin 2007; 46: 198-202.
6. Dietlein M, Dressler J, Eschner W et al. Procedure guideline for iodine-131 whole-body scintigraphy for differentiated thyroid cancer (version 3). Nuklearmedizin 2007; 46: 206-212.
7. Dietlein M, Dressler J, Grünwald F et al. Leitlinien zur Schilddrüsendiagnostik (Version 2). Nuklearmedizin 2003; 42: 109-115.
8. Dietlein M, Schober O, Schicha H. Über- oder Untertherapie des papillären Mikrokarzinoms der Schilddrüse? Überlegungen zur ablativen Radioiodtherapie. Nuklearmedizin 2004; 43: 107-114.
9. Geworski L, Lottes G, Reiners C, Schober O (Hrsg). Empfehlungen zur Qualitätskontrolle in der Nuklearmedizin - Klinik und Messtechnik. Stuttgart: Schattauer 2003.
10. 99mTc-uptake in autonomous thyroid tissue in Germany since the 1970s. Nuklearmedizin 2006; 45: 122-125.
11. Grünwald F, Biersack HJ. FDG-PET in thyroid cancer. J Nucl Med. 2000; 41: 1996-1998.
12. Lerch H, Schober O, Kuwert T et al. Survival of differentiated thyroid carcinoma studied in 500 patients. J Clin Oncol 1997; 15: 2067-2075.
13. Machens A, Holzhausen H-J, Dralle H. The prognostic value of primary tumor size in papillary and follicular thyroid carcinoma. Cancer 2005; 103: 2269-2273.
14. 131I activities and radioiodine therapy. Nuklearmedizin 2005; 44: 243-248.
15. 131I-induced release of "cold" iodine stored in the thyroid. Nuklearmedizin 2005; 44: 137-142.
16. Nakada K, Ishibashi T, Takei T et al. Does lemon candy decrease salivary gland damage after radioiodine therapy for thyroid cancer? J Nucl Med 2005; 46: 261-266.
17. Pacini F, Ladenson PW, Schlumberger M et al. Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study. J Clin Endocrinol Metab 2006; 91: 926-932.
18. Pacini F, Schlumberger M, Dralle H et al. and the European Thyroid Cancer Taskforce. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 2006; 154: 787-803.
19. Reiners C. Radioiodine therapy in patients with pulmonary metastases of thyroid cancer: when to treat, when not to treat? Eur J Nucl Med Mol Imaging 2003; 30: 939-942.
20. Reiners C. Diagnostik, Therapie und Nachsorge des Schilddrü senkarzinoms. 2. Aufl. Bremen, London, Boston: Unimed 2006.
21. Richtlinie Strahlenschutz in der Medizin 2002. 5. Auflage mit ausführlichem Erläuterungsteil von Kemmer W und Michalczak H. Berlin: H. Hoffmann Verlag 2003.
22. Riemann B, Schober O. Das kleine Schilddrüsenkarzinom. Nuklearmedizin 2007; 46: 113-114.
23. Rubino C, de Vathaire F, Dottorini ME et al. Second primary malignancy in thyroid cancer patients. Br J Cancer 2003; 89: 1638-1644.
24. Schicha H, Schober O. Nuklearmedizin. Basiswissen und klinische Anwendung. 6. Aufl., Stuttgart: Schattauer 2007.
25. Schlumberger M, de Vathaire F, Ceccarelli C et al. Exposure of radioactive iodine-131 for scintigraphy or therapy does not preclude pregnancy in thyroid cancer patients. J Nucl Med 1996; 37: 606-612.
26. Schuck A, Biermann M, Pixberg MK et al. Acute toxicity of adjuvant radiotherapy in locally advanced differentiated thyroid carcinoma. First results of the multicenter study differentiated thyroid carcinoma (MSDS). Strahlenther Onkol 2003; 179: 832-839.
27. Strahlenschutzverordnung. Textausgabe mit Anmerkungen von Witt E, Jäger E, Kasper L. 12. Aufl., Köln, Berlin: Carl Heymanns Verlag 2002.
28. Wichers M, Benz E, Palmedo H et al. Testicular function after radioiodine therapy for thyroid carcinoma. Eur J Nucl Med 2000; 27: 503-507.
29. Wittekind C, Meyer JH, Bootz F. TNM Klassifikation maligner Tumoren. 6. Aufl. Berlin: Springer 2003.
30. 18F]fluorodeoxyglucose uptake by differentiated thyroid carcinoma. Eur J Nucl Med Mol Imaging 2002; 29: 641-647.